Sentinel Network To Promote Medical Product Safety; Public Meeting, 7441 [07-710]
Download as PDF
Federal Register / Vol. 72, No. 31 / Thursday, February 15, 2007 / Notices
The number of respondents in Table
1 of this document are the number of
sponsors registered to make electronic
submissions (25). The number of total
annual responses is based on a review
of the actual number of such
submissions made between July 1, 2005,
and June 30, 2006. (156 x hours per
response (.08) = 12.5 total hours.)
Dated: February 8, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. E7–2579 Filed 2–14–07; 8:45 am]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N–0016]
Sentinel Network To Promote Medical
Product Safety; Public Meeting
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice; extension of registration
ycherry on PROD1PC64 with NOTICES
period.
SUMMARY: The Food and Drug
Administration (FDA) is extending to
February 28, 2007, registration for the
public meeting that will be held on
March 7 and 8, 2007, regarding FDA’s
exploration and development of an
integrated national network to link
private sector and public sector
postmarket safety efforts, creating a
virtual, integrated, electronic ‘‘Sentinel
Network’’. Such a network would
integrate existing and planned efforts to
collect, analyze, and disseminate
medical product safety information to
health care practitioners and patients at
the point-of-care. It would be
established through multiple, broadbased, public-private partnerships.
Dates and Times: The public meeting
will be held on March 7 and 8, 2007,
from 8 a.m. to 5 p.m.
Location: The public meeting will be
held at the University System of
Maryland Shady Grove Center, 8630
Gudelsky Dr., Rockville, MD 20850.
ADDRESSES: Submit written registration
to Erik Mettler, Office of Policy (HF–11),
Food and Drug Administration, 5600
Fishers Lane, rm. 14–101, Rockville, MD
20852, 301–827–3360, FAX: 301–594–
6777. Submit electronic registration to
Erik.Mettler@fda.hhs.gov.
For Registration to Attend and/or
Participate in the Meeting: Seating at the
meeting is limited. People interested in
attending should e-mail or submit
written registration to Erik Mettler (see
ADDRESSES) by close of business on
VerDate Aug<31>2005
18:37 Feb 14, 2007
Jkt 211001
February 28, 2007. Registration is free
and will be on a first-come, first-serve
basis. All individuals wishing to speak
during the open session of the meeting
must indicate their intent, the question
to be addressed, and provide an abstract
of the presentation by February 28,
2007.
We have set aside a portion of the
agenda (https://www.fda.gov/oc/op/
sentinel/) for individuals who would
like to make presentations at the
meeting. If you wish to make an oral
presentation during the open session of
the meeting, you must state your
intention on your registration
submission (see ADDRESSES). To speak,
submit your name, title, business
affiliation, address, telephone number,
fax number, and e-mail address. FDA
will do its best to accommodate requests
to speak. Individuals and organizations
with common interests are urged to
consolidate or coordinate their
presentations, and to request time for a
joint presentation. FDA may require
joint presentations by persons with
common interests. FDA will determine
the amount of time allotted to each
presenter and the approximate time that
each oral presentation is scheduled to
begin.
If you require special
accommodations due to a disability,
please inform Erik Mettler (see
ADDRESSES) when you register.
For Information On the Meeting
Contact: Erik Mettler (see ADDRESSES).
SUPPLEMENTARY INFORMATION: In the
Federal Register of January 18, 2007 (72
FR 2284), FDA announced a public
meeting to explore opportunities to link
private sector and public sector
postmarket safety efforts to create a
virtual, integrated, electronic ‘‘Sentinel
Network’’. Such a network would
integrate existing and planned efforts to
collect, analyze, and disseminate
medical product safety information to
health care practitioners and patients at
the point-of-care. It would be
established through multiple, broadbased, public-private partnerships. We
are seeking input on a number of
specific questions, included in the
original Federal Register notice,
regarding opportunities for
collaboration, the efficient use of
information technology, and the
collection and analysis of medical
product safety information. A tentative
agenda for the 2-day meeting has been
posted on FDA’s Web site and can be
viewed at https://www.fda.gov/oc/op/
sentinel/. We will post a final agenda by
March 1, 2007, at the same Web site.
During the course of the registration
period, FDA became aware that some
PO 00000
Frm 00055
Fmt 4703
Sfmt 4703
7441
registrations were not properly
recorded. Because of this and because of
the strong interest being expressed in
this meeting, the agency has decided to
reopen and extend the registration
period to February 28, 2007.
In light of the fact that we have
experienced some registration
difficulties, individuals who have
already registered can contact Erik
Mettler (see ADDRESSES) if they wish to
receive confirmation that their
registration has been recorded.
Interested parties who have not yet
registered may, on or before February
28, 2007, submit to Erik Mettler (see
ADDRESSES) an electronic or written
registration. Please include your name,
title, business affiliation, address,
telephone number, fax number, and email address. Please also indicate if you
wish to speak during the open public
session or if you would like to register
to make a presentation.
Dated: February 12, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 07–710 Filed 2–12–07; 2:59 pm]
BILLING CODE 4160–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007D–0040]
Draft Guidance for Industry on
Developing Products for Weight
Management; Availability
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is announcing the
availability of a draft guidance for
industry entitled ‘‘Developing Products
for Weight Management.’’ FDA is
interested in updating the September
1996 draft guidance entitled ‘‘Guidance
for the Clinical Evaluation of WeightControl Drugs’’ by incorporating the
latest scientific and clinical advances in
the drug development field of obesity,
including recommendations on the
development of products for weight
management in pediatric patients and in
patients with medication-induced
weight gain, and recommendations on
the development of combinations of
weight-management products. This
action is expected to provide clear and
consistent advice to those in industry
who are interested in developing
weight-management products.
DATES: Submit written or electronic
comments on the draft guidance by
E:\FR\FM\15FEN1.SGM
15FEN1
Agencies
[Federal Register Volume 72, Number 31 (Thursday, February 15, 2007)]
[Notices]
[Page 7441]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 07-710]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. 2007N-0016]
Sentinel Network To Promote Medical Product Safety; Public
Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice; extension of registration period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is extending to
February 28, 2007, registration for the public meeting that will be
held on March 7 and 8, 2007, regarding FDA's exploration and
development of an integrated national network to link private sector
and public sector postmarket safety efforts, creating a virtual,
integrated, electronic ``Sentinel Network''. Such a network would
integrate existing and planned efforts to collect, analyze, and
disseminate medical product safety information to health care
practitioners and patients at the point-of-care. It would be
established through multiple, broad-based, public-private partnerships.
Dates and Times: The public meeting will be held on March 7 and 8,
2007, from 8 a.m. to 5 p.m.
Location: The public meeting will be held at the University System
of Maryland Shady Grove Center, 8630 Gudelsky Dr., Rockville, MD 20850.
ADDRESSES: Submit written registration to Erik Mettler, Office of
Policy (HF-11), Food and Drug Administration, 5600 Fishers Lane, rm.
14-101, Rockville, MD 20852, 301-827-3360, FAX: 301-594-6777. Submit
electronic registration to Erik.Mettler@fda.hhs.gov.
For Registration to Attend and/or Participate in the Meeting:
Seating at the meeting is limited. People interested in attending
should e-mail or submit written registration to Erik Mettler (see
ADDRESSES) by close of business on February 28, 2007. Registration is
free and will be on a first-come, first-serve basis. All individuals
wishing to speak during the open session of the meeting must indicate
their intent, the question to be addressed, and provide an abstract of
the presentation by February 28, 2007.
We have set aside a portion of the agenda (https://www.fda.gov/oc/
op/sentinel/) for individuals who would like to make presentations at
the meeting. If you wish to make an oral presentation during the open
session of the meeting, you must state your intention on your
registration submission (see ADDRESSES). To speak, submit your name,
title, business affiliation, address, telephone number, fax number, and
e-mail address. FDA will do its best to accommodate requests to speak.
Individuals and organizations with common interests are urged to
consolidate or coordinate their presentations, and to request time for
a joint presentation. FDA may require joint presentations by persons
with common interests. FDA will determine the amount of time allotted
to each presenter and the approximate time that each oral presentation
is scheduled to begin.
If you require special accommodations due to a disability, please
inform Erik Mettler (see ADDRESSES) when you register.
For Information On the Meeting Contact: Erik Mettler (see
ADDRESSES).
SUPPLEMENTARY INFORMATION: In the Federal Register of January 18, 2007
(72 FR 2284), FDA announced a public meeting to explore opportunities
to link private sector and public sector postmarket safety efforts to
create a virtual, integrated, electronic ``Sentinel Network''. Such a
network would integrate existing and planned efforts to collect,
analyze, and disseminate medical product safety information to health
care practitioners and patients at the point-of-care. It would be
established through multiple, broad-based, public-private partnerships.
We are seeking input on a number of specific questions, included in the
original Federal Register notice, regarding opportunities for
collaboration, the efficient use of information technology, and the
collection and analysis of medical product safety information. A
tentative agenda for the 2-day meeting has been posted on FDA's Web
site and can be viewed at https://www.fda.gov/oc/op/sentinel/. We will
post a final agenda by March 1, 2007, at the same Web site.
During the course of the registration period, FDA became aware that
some registrations were not properly recorded. Because of this and
because of the strong interest being expressed in this meeting, the
agency has decided to reopen and extend the registration period to
February 28, 2007.
In light of the fact that we have experienced some registration
difficulties, individuals who have already registered can contact Erik
Mettler (see ADDRESSES) if they wish to receive confirmation that their
registration has been recorded.
Interested parties who have not yet registered may, on or before
February 28, 2007, submit to Erik Mettler (see ADDRESSES) an electronic
or written registration. Please include your name, title, business
affiliation, address, telephone number, fax number, and e-mail address.
Please also indicate if you wish to speak during the open public
session or if you would like to register to make a presentation.
Dated: February 12, 2007.
Jeffrey Shuren,
Assistant Commissioner for Policy.
[FR Doc. 07-710 Filed 2-12-07; 2:59 pm]
BILLING CODE 4160-01-S